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ABSTRACT The present study is devoted to the feasibility of expressing  the single-domain mini-antibody (na-
noantibody) selected from the library of sequences of the variable domains of special single-stranded antibodies 
derived from an immunized camel, a gene of which was introduced into eukaryotic cells within a recombinant 
adenoviral vector. A vector bearing the gene of a single-domain nanoantibody was obtained using the AdEasy 
Adenoviral Vector System (Stratagene). This method of delivering the nanoantibody gene facilitates  efficient 
expression of this gene and  functional activity of the nanoantibody. The results obtained can be used to produce 
passive immunizing tools against pathogens or new-generation immunobiological antitoxic medication.
KEYWORDS recombinant adenoviral vector; nanoantibodies; genetic immunization.
ABBREVIATIONS HEK-293 – human embryonic kidney cell culture; His 6-tag - amino acid motif in proteins 
consisting of six histidines; НА-tag – epitope tag (YPYDVPDYA) derived from the haemagglutinin molecule; 
PFU – plaque-forming unit; PCR – polymerase chain reaction; PT-PCR – reverse transcription polymerase chain 
reaction; GAPDH - glyceraldehyde 3-phosphate dehydrogenase.
INTRODUCTION
Antibodies are the primary tools of the immune sys-
tem, which participate in the protection of the organ-
ism against pathogenic microorganisms. The signifi-
cance of antibodies is growing   as researchers become 
aware  of their potential not only as tools to be used in 
diagnostics, but  in therapy as well [1]. Antibodies have 
been successfully used to treat certain forms of onco-
logical conditions. Over the past decades, monoclonal 
antibodies have been widely used in diagnostics and 
for research purposes. Yet, the conventional methods 
used to obtain monoclonal antibodies, based on dealing 
with animal-origin cells, make difficult their use as 
therapeutic agents.  Introduction of these monoclonal 
bodies into the human organism may result in the on-
set of an undesirable immune reaction, particularly, if 
used repeatedly [2]. In order to prevent the emergence 
of such an immune response, the following approaches 
have been developed: production of recombinant im-
munoglobulins in which the regions that are not re-
sponsible for antigen recognition are replaced by  cor-
responding fragments of human origin (humanized 
antibodies), or removal of the domains that are not 
involved in antigen binding (mini-antibodies). The so-
called recombinant technologies, based on the use of 
libraries comprising sequences from human antibod-
ies, have found increasing application over the past 
decade. When constructing these libraries, variable 
domains of the heavy and light strands are linked in 
the expression vector via random screening within 
one reading frame via the linker sequence [3]. It is 
rather laborious to deal with cumbersome libraries of 
these single-stranded antibodies (scFv), and only in 
rare cases is a highly affine antibody  finally obtained. 
Certain difficulties are associated with the instability 
of genetic constructions, the low level of product ex-
pression, and its solubility [4].
A significant breakthrough in this field has been 
the detection of non-canonical antibodies in mem -
bers of the Camelidae biological family. These anti-
bodies do not contain light strands and represent a 
dimer of shortened heavy strands [5, 6]. An immune 
response with the participation of these antibodies 
can be induced by  conventional immunization. There 
are a number of advantages in using the repertoire of 
these non-canonical antibodies to create libraries of 
sequences of variable domains (for the heavy strand 
only). The single-domain structure of the recognizing RESEARCH ARTICLES
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variable domain stipulates a small size of the antigen-
binding fragment (mini-antibodies),  high stability, 
and solubility [7].
Thanks to their structure, mini-antibodies can be 
used to reveal epitopes that are hidden for the conven-
tional immunoglobulins. The expression from a single 
gene simplifies genetic engineering procedures and, 
therefore, the work with the libraries containing the 
sequences of variable domains. Low immunogenicity 
(conditioned by the high homology of the sequences 
of mini-antibodies with a variable domain of heavy 
strands of human IgG3) and the relative simplicity of 
the humanization procedure open broad opportunities 
for the application of mini-antibodies in the design of 
novel pharmaceutical agents [8].
These features of the structure of mini-antibodies 
and the simplicity with which   their genes can be ma-
nipulated enable  efficient and economical production 
of large amounts of a mini-antibody, using various ex-
pression systems [9]. 
The use of the prokaryotic expression system to pro-
duce mammalian proteins has to do with the possibly 
low functional activity of the proteins obtained, due to 
the absence of a system for post-translational modifi-
cation in prokaryotic cells. Moreover, no matter how 
thorough the purification, the final product can still be 
contaminated with pyrogenes.
One of the promising methods for delivering  genetic 
material to  target cells is the use of viral vectors.  Ex-
pression constructions bearing one or several recom-
binant genes are incorporated into the viral genome 
using  methods of genetic engineering.  Vectors based 
on the genome of the adeno-associated virus have been 
proposed in a number of studies [10, 11] for delivery of 
mini-antibody genes to  target cells.
Adenoviral vectors are among the most universal 
tools used for delivery and expression of recombinant 
genes in mammalian cells. It is known that recom -
binant adenoviruses efficiently transfer the genes of 
bacterial and viral antigens, cytokines, growth fac-
tors, and other proteins to the target cells, ensuring a 
high level and duration of  target gene expression [12]. 
Adenoviral vectors are capable of transducing both 
dividing and postmitotic cells. Adenoviral DNA re-
mains in its extrachromosomal form, whereas the re-
combinant virus is excreted from the organism within 
4–5 weeks [13, 14].
The production of recombinant adenoviruses is char-
acterized by the following feature: the virus is capable 
of reproducing only in vitro in special cell lines, which 
ensures the vector’s safety [15]. 
The fact that  recombinant adenoviral vectors can be 
used efficiently for the expression of antigen-binding 
fragments of antibodies is borne out by the example 
of mini-antibodies to the cell epitope (the epidermal 
growth factor receptor (erbB-2) and anthrax toxin 
component) [16, 17].
The aim of the present work is to examine how  re-
combinant adenoviral vectors can be used for delivery 
and efficient expression of single-domain mini-anti-
bodies (nanoantibodies) obtained using the novel tech-
nology of  generation of special single-stranded anti-
bodies extracted from camel. The nanoantibody earlier 
obtained and characterized to the cell cytokeratine-8 
[18] was selected as the model antibody. It was subse-
quently used to demonstrate the fundamental possibil-
ity of  expressing the single-domain antibodies obtained 
by immunization of  members of the Camelidae family 
via recombinant adenoviruses.
EXPERIMENTAL
Enzymes
In this study, restriction endodeoxyribonucleases, T4 
DNA ligase, alkaline phosphatase (CIAP) purchased 
from Fermentas MBI (Lithuania), and Taq-polymer-
ase purchased from Promega (United States) were 
used.
Cell lines
The HEK-293 cell line (human embryonic kidney cell 
culture transformed by the E1-region of human ad-
enovirus serotype 5) and Н1299 cell line (human lung 
cancer cells) were used. The cells were cultured in a 
DMEM medium containing 10% of fetal bovine serum 
(FBS) purchased from HyClone (United States).
Production of the cDNA clone encoding 
the single-domain mini-antibody 
(nanoantibody) which specifically recognizes 
the endogenous mouse cytokeratin-8
Antibody aCyK-VHH, which specifically recog-
nizes mouse cytokeratin-8, was obtained earlier by 
S.V. Tillib’s research group ( Institute of Gene Biology, 
Moscow) in collaboration with the laboratory headed 
by S. Muyldermans (Vrije Universiteit Brussel) and 
used (via binding to the fluorescent protein sequence) 
to obtain fluorescent nanoantibodies (or chromobod-
ies) aimed at demonstrating the new method for trac-
ing  antigens in a living cell. It should be noted that 
the aCyK-VHH nanoantibody was one of the first an-
tibodies to endogenous structural eukaryotic proteins. 
The first stage of its production comprised immuniza-
tion of the Bactrian camel (Camelus bactrianus) with 
a protein extract from mouse soft tissue cells (pre -
dominantly from the liver). The subsequent selection 
procedure, based on the phage display method, was 
performed as described in the online supplement to 66 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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the article [18]. The fundamental stage after selection 
of the most enriched antibody clones was the identi-
fication of the unknown antigen recognized by these 
nanoantibodies. The proteins from the nanoantibody-
binding region upon Western blotting were addition-
ally separated by electrophoresis to obtain individual 
products. Western blotting was then used to analyze 
the recognition of each product by a nanoantibody. 
The product recognized by a nanoantibody was identi-
fied using mass spectrometrical analysis of its trypsin 
hydrolysate. The resulting nanoantibody aCyK-VHH 
recognized cytokeratin-8, a fact attested to via the im-
munofluorescent staining of С2С12 (mouse myoblast 
cell line) with these antibodies, revealing the charac-
teristic distribution of cytokeratin intermediate fila-
ments in the cytoplasm.
The nanoantibody aCyK-VHH produced in the bacte-
rial periplasm was modified by binding an antigen-rec-
ognizing sequence of two additional small fragments, 
epitope of influenza virus haemogglutinine (HA-tag) 
and six histidine residues (His6-tag), in order to purify 
it and simplify its detection.
Obtaining recombinant adenovirus
Plasmids and the recombinant adenoviral vector were 
obtained using the gene of antibody to cytokeratin 
aCyK-VHH. The nucleotide sequence encoding the 
nanoantibody was obtained by chemical synthesis in 
“Evrogen” JSC. The AdEasy Adenoviral Vector Sys-
tem (Stratagene, United States) was used in order to 
construct the рAd-aCyK-VHH plasmid vector contain-
ing the genome of the recombinant adenovirus with 
E1 region deletion, and a transgene expression cassette 
incorporated instead of it via homologous recombina-
tion in E. coli cells. The recombinant adenovirus was 
obtained via transfection of HEK-293 cell lines with 
the рAd-aCyK-VHH plasmid construct linearized on 
the PacI site. Lipofectamine 2000 (Invitrogen, United 
States) was used for the transfection, according to the 
manufacturer’s recommendations. The recombinant 
human adenovirus of serotype 5 with E1 region dele-
tion and an incorporated transgene-free cassette ex-
pression (Ad-null) inserted instead of it was used as the 
control.
To accumulate adenoviral preparations, an infect-
ed cell suspension (107 PFU of the virus per Petri dish 
with a diameter of 15 cm) was coated to the HEK-293 
cell monolayer with 50–70% confluence. The infected 
cell suspension was destroyed by three freeze-thaw 
cycles and clarified by centrifuging (2000 rpm, 10 min, 
+4°С).
The titres of the specimens Ad5-aCyK-VHH and Ad-
null (108 PFU/ml) were determined by the plaque for-
mation technique in the HEK-293 cell culture.
Infection of cells with  
a recombinant adenovirus
Approximately 106 cells of the H1299 line were infected 
with recombinant adenoviruses. The cells were seeded 
to ~ 70% of the monolayer, cultivated for 24 h, and in-
fected with the recombinant adenovirus (the multiplic-
ity of infection being 100 PFU/cell) in a DMEM me-
dium containing 2% of FBS. Two hours after the viral 
preparation was introduced, the medium was collected, 
the cell culture was washed, and a fresh DMEM me-
dium was added. The medium from the infected cells 
was collected 72 h after infection and concentrated by 
centrifuge ultrafiltration through a membrane with 
a nominally intercepted molecular weight of 10 kDa. 
After thickening by a factor of 10, the supernatant was 
fractioned in a 10% polyamide gel and used for immune 
blotting analysis.
Antigen preparation
Homogenized mouse liver lysate (BALB/c line) was 
obtained via extraction with the use of a RIPA buffer 
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, protease inhibitor kit (Roche, 
Switzerland)). The concentration of the total protein in 
the specimens was determined by the Bradford method 
(Sigma-Aldrich, United States). The specimens with an 
equal protein concentration were applied to the gel to 
be separated by electrophoresis.
Polyacrylamide gel electrophoresis 
and immunoblotting
Cellular proteins were separated by polyacrylamide 
gel electrophoresis by the Laemmli procedure under 
denaturing conditions in the presence of sodium do-
decyl sulphate. Protein Test Mixture 4 (Serva, Germa-
ny) was used as the molecular weight standard. After 
the gel electrophoresis, the proteins were placed onto 
a Hybond-P PVDF membrane (GE Healthcare, United 
States) using a TE70 Semi-Dry Transfer Unit (Hoefer 
Scientific, United States) in accordance with the manu-
facturer’s recommendations. The nanoantibodies were 
detected using the Monoclonal Anti-HA–Peroxidase 
antibody (Sigma-Aldrich, United States). The immobi-
lized proteins were detected using ECL Plus Western 
Blotting Detection Reagents (GE Healthcare, United 
States) in accordance with the manufacturer’s recom-
mendations. The chemilumenscent radiation was re-
corded with the aid of an Amersham Hyperfilm ECL 
X-ray film (GE Healthcare, United States).
RESULTS
As a result of the earlier performed selection of the 
phage library of the antigen-binding domains of single-
stranded antibodies, DNA from the pHEN4 phagemid RESEARCH ARTICLES
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with an insertion encoding the nanoantibody, which 
has a high affinity towards the structural cytoplasmat-
ic mouse protein, cytokeratin-8, was collected. The data 
on the structure of the target protein were obtained 
via mass spectrometric identification. The nucleotide 
sequence encoding the nanoantibody was cloned in the 
recombinant adenoviral vector.
A leading peptide of the mouse immunoglobulin 
κ-chain was bound to its N-terminus, in order to en-
sure  efficient extracellular expression of a nanoanti-
body. The HA-tag, which is effectively recognized by 
commercial antibodies,  a requirement for confirming   
nanoantigen expression at the protein level, was bound 
to the C-terminus of the nanoantibody. Figure 1 shows 
the scheme of the resulting construct.
In order to construct the adenoviral vector, the se-
quence encoding the HA-tag-labelled аCyK-VHH anti-
body was cloned in the shuttle plasmid vector pShuttle-
CMV (Stratagene, United States). This vector contains 
terminal fragments of the human adenovirus serotype 5 
genome, the expression cassette containing the human 
cytomegalovirus promoter (CMV) and polyadenylation 
signal. The presence of the insertion and its orientation 
were confirmed by restriction mapping.
The recombinant plasmid adenoviral vector bearing 
the target gene was obtained via homologous recombi-
nation in E. coli cells. The plasmid construct obtained 
contained the replication initiation site ori, the gene of 
antibody resistance, and a cassette with the target gene 
within the adenoviral genome. The main advantage of 
this method is the potential utilization of E. coli cells as 
the main tools for cloning, recombination, and produc-
tion of adenoviral DNA in preparative amounts. The 
opportunity to perform the homologous recombination 
in E. coli cells makes it possible to deal with the indi-
vidual clones containing plasmid constructs only with 
recombinant adenoviruses, which eliminates the pos-
sibility of contamination with a wild-type adenovirus.
The shuttle plasmid construct bearing the expression 
cassettes with the nanoantibody gene was linearized on 
the PmeI site and introduced along with pAd-EASY 
(Stratagene) to E. coli BJ5183 cells by electroporation. 
Recombinant clones obtained by homologous recombina-
tion were collected on the selective kanamycin-contain-
ing medium (50 µg/ml). The presence of recombinant 
clones of nucleotide sequences encoding the aCyK-VHH 
antibody and human adenovirus serotype 5 fibre in plas-
mid DNA was analyzed by PCR with specific primers 
and via restriction mapping, using HindIII restrictase, 
which enables one to obtain a restriction pattern that is 
typical for the human adenovirus genome.
HEK-293 cells were transfected with a plasmid 
cleaved at the PacI site and containing the recombinant 
adenovirus genome with  E1 region deletion and the 
expression cassette with a transgene inserted instead of 
it. The resulting recombinant adenovirus Ad5-aCyK-
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VHH was analyzed by PCR using the primer pair that 
was complementary to the target gene, the hexon gene 
of human adenovirus serotype 5, and the E1 region of 
the adenovirus in order to control the possible presence 
of replication-competent viral particles. 
Detection of the expression of the  
nanoantibody gene within the recombinant 
adenovirus Ad5-aCyK-VHH
The expression of the target gene within the recom-
binant human adenovirus serotype 5 Ad5-aCyK-VHH 
was analyzed at the level of the mRNA. With this pur-
pose in mind, the cells of the HEK-293 line that are per-
missive for human adenovirus serotype 5 were infected 
with the recombinant virus Ad5-aCyK-VHH. The total 
RNA of infected cells was used to produce DNA, which 
was analyzed by PCR with primers specific to the se-
quence of the nanoantibody gene to mouse cytokeratin 
8, to viral DNA, and the constitutively expressed gene of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
HEK-293 cell lines infected with Ad-null virus (Fig. 2A) 
were used as the negative control. RT PCR was used to 
demonstrate that the recombinant adenoviral vector ex-
presses mRNA of the nanoantibody gene to cytokeratin 
and can be used to analyze protein production.
Nanoantibody expression at the translational level 
was analyzed in H1299 cells infected with the recom-
binant adenovirus carrying the gene of nanoantibody 
to aCyK-VHH tagged with HA-epitope of the influenza 
virus (Ad5-aCyK-VHH), and the recombinant adenovi-
rus containing the transgene-free expression cassette 
(Ad-null). The presence of a nanoantibody in the cul-
ture medium containing the infected cells was meas-
ured by immunoblotting with antibodies to HA-epitope 
of the influenza virus conjugated with horseradish per-
oxidase (Fig. 2B).
Biological activity
The specificity of a nanoantibody expressed by the ad-
enoviral vector to cytokeratin was confirmed by means 
of comparison of the interaction between the antigene 
and the proteins of the cultural fluid from the cells in-
fected with recombinant adenovirus, and the interac-
tion between the antigene and the antibody purified 
from E. coli periplasm. 
The lysates of mouse liver and cerebrum cells were 
fractioned in a polyacrylamide gel, transferred to the 
PVDF membrane, which was incubated with the cul-
tural medium of the cells infected with Ad5-aCyK-
VHH. The expressed nanoantibody served as the prima-
ry antibody to the target protein (mouse cytokeratin-8, 
55 kDa) detected in the total lysate. The membrane was 
simultaneously incubated with antibodies aCyK-VHH 
produced in E. coli periplasm.
Figure 3 shows the results of an electrophoresis of 
protein lysates in polyacrylamide gel and the data ob-
tained by immunoblotting with nanoantibodies aCyK-
VHH after  development by secondary antibodies to 
the HA-epitope of the influenza virus conjugated with 
horseradish peroxidase.
Immunoblotting results attest to the fact that the an-
tibody expressed by the adenovirus has the same spe-
cificity as the antibody synthesized in E. coli periplasm, 
its gene being cloned in the recombinant adenovirus.
DISCUSSION
At the time of writing, there were a number of tech-
nologies capable of producing mini-antibodies with a 
predetermined specificity. Only quite recently was it 
revealed that, in addition to the canonical antibodies, 
functionally active noncanonical single-stranded an-
tibodies were  produced in relatively large amounts 
in members of the Camelidae family. Therefore, it is 
now possible to obtain mini-antibodies on the basis of   
aCyK-VHH
Fib Ad5
GAPDH
Ad- 
aCyK- 
VHH
Ad-
null
Ad-null
K+ 
HA- 
tag
Ad5-
aCyK-
VHH
20 kDa
15 kDa
A B
Fig. 2. The analysis of anti-cytokeratin nanoantibody 
expression in cells infected with recombinant adenovirus. 
A – Expression of anti-cytokeratin nanoantibody gene in 
cells infected with recombinant adenovirus Ad5-aCyK-
VHH was analyzed using reverse transcription (RT)-PCR, 
cDNA encoding this gene was amplified by PCR with 
primers specific to the gene of the anti-cytokeratin na-
noantibody (aCyK-VHH), Ad5 fiber gene (Fib Ad5), and 
house-keeping gene GAPDH. A recombinant adenovirus 
with no transgenic insertions in the E1 deletion region of 
the adenoviral genome (Ad-null) was used as the specifi-
city control. B – The expression of the anti-cytokeratin 
nanoantibody was detected by hybridization with anti-HA 
antibodies in a Western blot analysis. A protein with a 
molecular weight of 15 kDa was detected in the cultural 
fluid of cells infected with the recombinant adenovirus. 
The (His6)-tagged nanoantibody produced in E. coli was 
used as the control of the specificity of the interaction 
between anti-HA antibodies and the target protein.RESEARCH ARTICLES
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libraries containing the antigen-recognizing domains 
of single-stranded antibodies of immunized animals. 
Noncanonical antibodies consist of a dimer with a single 
shortened heavy immunoglobulin chain (containing no 
light chains). Single-domain mini-antibodies (nanoan-
tibodies) are genetically engineered derivatives of the 
antigen-recognizing domains of these noncanonical 
antibodies. The selection of clones of a mini-antibody 
with the predetermined specificity from the library 
of sequences of the entire repertoire of antigene-rec-
ognizing domains of noncanonical antibodies obtained 
from immunized camel is based on the highly efficient 
procedure of functional selection of filamentous phage 
particles containing both an exposed mini-antibody on 
the surface, and the DNA encoding it within the phage 
particle (phage display).
Mini-antibodies produced by this technology are 
characterized by high stability, solubility, and low im-
munogenicity. Mini-antibodies can be produced (select-
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Fig. 3. Western blot detection of the functional activity of 
nanoantibodies. Total cell extracts of liver (lanes 1, 3) and 
brain (lanes 2, 4) cells were separated on a SDS–PAGE 
and electrophoretically transferred to a PVDF-membrane. 
The specific interaction of the target protein (~ 55 kDa) 
with the anti-cytokeratin nanoantibodies obtained in the 
cultural fluid of cells infected with the recombinant adeno-
virus and periplasm of E. coli was detected by immunob-
lotting.
ed) to any antigens and any antigen epitopes, includ-
ing conservative ones, which often cannot be produced 
using the conventional procedure. Since the encoding 
nucleotide sequence is known for each mini-antibody, 
it is possible to produce the corresponding protein in 
any of the known expression systems (prokaryotic and 
eukaryotic).
It is economically viable to produce protein prepara-
tions of mini-antibodies in E. coli cells, yeast, or CHO 
cells. When injecting these preparations to experimen-
tal animals (or patients), their very short lifetime in the 
organism (less than 24 h) should be taken into account. 
The period of therapeutic action of preparations based 
on mini-antibodies can be increased using the vector 
systems, providing that the synthesis of the active 
agent takes place immediately in the infected cells of 
the organism. Recombinant adenoviruses are the opti-
mal expression system for solving such problems. Their 
safety and efficiency has been proved in a number of 
clinical trials performed globally; the time needed to 
produce a target protein is approximately 20 days. 
The potential application of recombinant adenoviral 
vectors for the expression of the genes of the antigen-
recognizing fragments of single-stranded antibodies ob-
tained from Bactrian camel was studied in this work. It 
was demonstrated that expression of the nanoantibody 
gene using the adenoviral vector is possible. Transgene 
expression was confirmed at the level of the RNA tran-
script and protein product. The specific interaction of 
the nanoantibody secreted by eukaryotic cells with a 
target protein attests to the fact that its functional ac-
tivity is retained. Further studies are necessary for a 
qualitative estimation of the efficiency of nanoantibody 
expression using a recombinant adenovirus.
CONCLUSIONS
The delivery of the gene of a single-domain mini-an-
tibody (nanoantibody) selected from the library con-
taining  sequences of the variable domains of specific 
single-stranded antibodies of immunized camel to eu-
karyotic cells using the recombinant adenoviral vec-
tor provides efficient expression and functioning of 
the nanoantibody. The results of this study can be used 
for the production of passive immunization agents for 
protection against pathogens, or for the design of new-
generation immunobiological antitoxic preparations. 
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